Kesios Gets Funding To Explore Novel Multiple Myeloma Pathway
This article was originally published in Scrip
British biotech start-up Kesios Therapeutics Ltd aims to use funds from its £19m ($28.5m) Series A financing, completed Dec. 2, to place its lead candidate drug KES-0001 in clinical studies as a potential treatment for multiple myeloma.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.